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Abstract  
Objective: Most prolactinomas in females are diagnosed during the reproductive age and the majority 
are microadenomas. Prolactinomas detected in the postmenopausal period are less common with 
limited published data on their presentation and prognosis. Our objective was to assess the presenting 
clinical, biochemical and imaging findings, as well as the outcomes of women diagnosed with a 
prolactinoma in the postmenopausal period.   
Design and Methods: We undertook a retrospective cohort study of women diagnosed with 
prolactinoma after menopause and followed-up in a large UK pituitary center. Information on 
presentation, management and outcomes were collected.  
Results: Seventeen women with a median age at diagnosis of 63 years (range 52-78) were identified. 
Headaches and/or visual deterioration were the most commonly reported complaints at detection of 
the adenoma (47%). Acute pituitary apoplexy was diagnosed at presentation or during follow-up in 
18% of the cases. The median serum prolactin was 12364 mU/L (range 2533-238479). 
Macroprolactinomas comprised 94% of the tumours, and 88% of them had supra/parasellar extension. 
All patients with macroprolactinoma were offered dopamine agonist and normal prolactin was 
achieved in 94% of them (median follow-up 91.5 months). Adenoma shrinkage was observed in all 
women. Improvement or resolution of visual disturbances documented at presentation was observed 
in 86% of cases. 
Conclusions: The clinical phenotype of prolactinomas diagnosed in the postmenopausal period is 
characterized by dominance of macroadenomas, with frequent supra/parasellar extension and a 
relative high rate of acute pituitary apoplexy. In this group of patients, the response of the 
macroadenomas to dopamine agonists is good.    
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Introduction  
Prolactinomas have a prevalence of 35-44/100,000 population and are the most common pituitary 
adenomas diagnosed in women (1-3).  Most prolactinomas in females are diagnosed during the years 
of reproductive age (median 30.5-32 years), and the majority are microadenomas (1,3) that show a 
high response rate to cabergoline (93%) (4). In contrast, prolactinomas in males are diagnosed at an 
older age (median 41.5-47.5 years) and are mostly macroadenomas (1,3).  
Experimental data in rats have shown that ooophorectomy has a dramatic effect on lactotroph cells, 
with a decrease in their size and number, as well as a reduction in the intracellular abundance of PRL-
secretory granules; all these effects are reversed by estradiol (5). Interestingly, in vivo estrogen 
administration induces lactotroph tumours in rats (6) and selective antiestrogen treatment inhibits 
lactotroph tumour growth in rats harboring subcutaneous implanted PRL-secreting pituitary tumours 
(7). Although a number of studies in humans do not support an association between use of oral 
contraceptives or estrogen replacement therapy and prolactinoma formation or growth in women (at 
least in microadenomas), these adenomas may enlarge during pregnancy, and cases of prolactinomas 
occurring after long-term estrogen therapy in male-female transsexuals have been reported (8,9). 
Menopause, a physiological state of hypoestrogenism, can have a beneficial effect on the natural 
history of hyperprolactinemia. A small number of studies have shown that long-term reduction or 
normalization of PRL in women with microprolactinoma after the cessation of their menses can occur 
(10,11), and, therefore, stopping treatment with dopamine agonist may be a justified approach.  
Females diagnosed with a prolactinoma in the postmenopausal period represent a less common and 
possibly under-recognized group, as the compromised ovarian function alters the presenting clinical 
manifestations and the changes in the estrogen status may have an impact on the natural history of the 
tumour. In fact, epidemiological studies report standardized incidence rates of around 1/100,000 for 
prolactinomas diagnosed in females aged above 50 years (2,3). As a result of this, data on their 
clinical phenotype, natural history and outcomes are extremely limited, with only a single report 
published to date (12); this involved a case series of 14 patients from three different Endocrine 
outpatient clinics in three academic centers from Israel, USA and Brazil. Therefore, and taking into 
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account the reported impact of menopause on PRL secretion, studies providing further insight on this 
specific group of patients would be of value in clinical practice.  
The aim of our study was to assess the clinical, biochemical and imaging findings at presentation and 
during follow-up, as well as the outcomes of women diagnosed with a prolactinoma during the post-
menopausal period and managed in a single pituitary center in the UK.   
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Patients and Methods 
 
Patients  
All females with a prolactinoma diagnosed in the postmenopausal period (mean age of menopause in 
the UK 51 years) and reviewed in the Department of Endocrinology, Queen Elizabeth Hospital 
Birmingham, UK between 1996 and 2016 were studied. These were identified through searches by the 
University Hospitals Birmingham IT Services in the electronic patient record, as well as through 
searching the Departmental database. The diagnosis of prolactinoma was based on the detection of 
hyperprolactinemia (after excluding the presence of macroprolactin and secondary causes explaining 
the PRL levels) combined or not with the identification of an adenoma on pituitary imaging; it was 
further supported by shrinkage of the tumour in cases in which dopamine agonist therapy was offered 
or by the presence of positive PRL immunostaining in tumours surgically resected. Clinical, 
biochemical, imaging findings and medications at presentation and follow-up, as well as information 
on the management and outcomes of the patients were collected.  
In cases in which dopamine agonist therapy was offered, the dose was gradually titrated until 
achievement of normal PRL or until maximum tolerated dose was achieved. Pituitary imaging was 
performed within 6 months after starting treatment and at clinically indicated intervals thereafter. The 
assessment of visual fields was performed by Goldman perimetry.  
The study was completely retrospective in nature and involved no intervention beyond routine patient 
care. It was registered with and approved as an audit by the University Hospitals Birmingham NHS 
Foundation Trust.   
 
Prolactin assay 
The serum PRL was measured between 1996 and 2000 by a Corning ACS immunometric assay, 
between 2000 and 2006 by a Bayer Advia Centaur immunometric assay (reference range for both 
assays: males 40-360 mIU/L; females 60-620 mIU/L), and between 2006-present by an E170 Roche 
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Diagnostics immunometric assay (reference range: males 85-325 mIU/L; females 100-500 mIU/L). 
All assays were standardised to IRP 84/500. 
 
 Statistics 
Percentages were calculated for categorical data and medians with ranges for continuous variables. 
Correlation between age and PRL levels at diagnosis were performed by the Pearson’s correlation 
method. The level of significance was set at p<0.05. Statistical analyses were performed by IBM 
SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.  
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Results  
Seventeen women diagnosed with a prolactinoma at a median age of 63 years (range 52-78) were 
identified. No patient was on estrogen replacement therapy at the time of detection of the tumour. The 
presenting clinical, biochemical and imaging manifestations are shown in Table 1.  
Headaches and/or visual deterioration were the most commonly reported complaints at detection of 
the adenoma [8/17 (47%)]. Two patients presented with pituitary apoplexy [2/17 (12%)]; in one of 
them, serum PRL was normal at the time of apoplexy, which was managed by transsphenoidal surgery 
(pathology consistent with a necrotic pituitary adenoma); seven years later, PRL was found at 12364 
mU/L, leading to the final diagnosis of prolactinoma. The second case of apoplexy was managed 
conservatively. Two prolactinomas were detected incidentally (12%).   
In terms of menstrual history, five women had a history of amenorrhea for which they had no 
investigations during the reproductive age; their prolactinoma was diagnosed at the ages of 52, 60, 63, 
65 and 66 years; two had hysterectomy at the age of 29 and 34 and were diagnosed when 70 and 58 
years, respectively; in all other cases, early menopause was not reported.   
All patients except one (who had a 5 mm adenoma) had macroprolactinoma (16/17, 94%), with 
supra/parasellar extension in 15/17 of them (88%).  Visual field defects attributed to pressure on the 
optic pathways by the adenoma were identified in 7/17 (41%) patients.  
The serum PRL of the single microprolactinoma patient was 2533 mU/L; in those with 
macroprolactinoma, the median value was 18553 mU/L (range 4153-238479). There was no 
significant correlation between age and PRL levels at diagnosis. In all cases, IGF-I values were not 
consistent with GH hypersecretion. At diagnosis, two patients were put on glucocorticoid replacement 
for ACTH deficiency and four were on Levothyroxine.  
The management and the outcomes of the patients are shown in Table 2. The patient with the 
microprolactinoma was not treated with dopamine agonist and her PRL rose from 2533 to 3227 mU/L 
during a follow-up period of 51 months; pituitary MRI 26 months after the original imaging did not 
identify an adenoma. During follow-up, she was on opiates for pain relief, which may have 
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contributed to persistence of the hyperprolactinemia. All patients with macroprolactinoma were 
offered dopamine agonist therapy (cabergoline n=13, bromocriptine n=2, quinagolide n=1). The 
median duration of their follow-up, determined by the date of starting dopamine agonist until last 
serum prolactin measurement, was 91.5 months (range 5-222). Normal PRL was achieved in 15/16 
(94%) patients, and this did not prompt menstrual bleeds in any of them [their gonadotropins 
remained suppressed (n=10) or reached the menopausal levels (n=6)]. Adenoma shrinkage was 
observed in all women (ranging from 25% reduction in maximum diameter up to complete adenoma 
resolution on latest imaging). All but one patients (6/7, 86%) had improvement or resolution of the 
visual disturbances documented at presentation. One patient presented with apoplexy (sudden onset 
headache and right visual loss) eight months after starting cabergoline; she was surgically managed 
(pathology: adenoma with immunostaining positive for PRL and focal apoplexy) and restarted 
cabergoline due to residual adenoma. Treatment was stopped in two patients [one on cabergoline 
following her choice with PRL showing slight increase 6 months later (561 mU/L, 100-500), and one 
on bromocriptine with PRL increasing due to commencing olanzapine, but with imaging 10 months 
later not showing adenoma enlargement]. 
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Discussion 
This is the largest study to date assessing the clinical phenotype and outcomes of consecutive cases of 
prolactinomas diagnosed at the postmenopausal period. While in premenopausal women 
microprolactinomas dominate, we found that 94% of the tumours newly diagnosed in our 
postmenopausal patients were macroadenomas, and these caused headaches and/or visual 
deterioration in almost half of the cases. Despite the size of the tumours (macroadenomas with 
supra/parasellar extension in 88% of them), the response to dopamine agonists was very good, both in 
terms of achieving normal PRL and adenoma shrinkage. Interestingly, apoplexy was seen in 18% of 
the cases at diagnosis or during follow-up.  
The absence of menstrual irregularities in postmenopausal women harboring a prolactinoma results in 
a different clinical phenotype leading to diagnosis of the tumour. Thus, the sequelae of 
hyperprolactinemia are not evident (apart from the rare cases of galactorrhea) and the consequences of 
a pituitary mass lesion, headaches and/or visual disturbances, are the most common presenting 
manifestations (47% in our series). Interestingly, two cases (12%) were diagnosed incidentally and 
involved adenomas with PRL of 9046 and 11401 mU/L, respectively, and minimal or no suprasellar 
extension. It is also of note that five women had a history of long-standing amenorrhea for which no 
investigations had been carried out during reproductive age; their macroadenoma was diagnosed 
between the ages of 52-66 years. Although these may not relate with the prolactinoma, the long-
standing presence of the tumour cannot be excluded, reflecting the natural history of untreated 
prolactinoma.   
Interestingly, pituitary apoplexy was the first presentation in two of our patients. Although extracted 
from a small number of cases, this percentage is remarkable compared with the reported apoplexy rate 
of 0.81% in a series of 368 prolactinomas treated in a single center during a period of 11 years (upper 
interquartile range for age at diagnosis in females and males: 37 and 54.5 years, respectively) (13). In 
the same paper, macroadenoma and female gender were strongly predictive of the presence of 
pituitary hemorrhage (not necessarily associated with clinical picture of apoplexy) on MRI (13). A 
rapidly expanding adenoma that outstrips its blood supply and results in ischemia/hemorrhagic 
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infarction, as well as compression of the pituitary vessels at the diaphragmatic notch have been 
proposed as potential mechanisms (13,14). In our study, pituitary apoplexy was diagnosed in a third 
patient 8 months after starting cabergoline. This necessitated transsphenoidal surgery due to visual 
deterioration; cabergoline was subsequently restarted with no further apoplectic event as of latest 
assessment. Cases of patients with pituitary apoplexy whilst on dopamine agonist have been 
previously described (15); a potential causal link and the mechanism of this remain to be clarified.  
Overall, the rate of apoplexy in our patient group was 18%. It is of note that in epidemiological 
studies looking at the prevalence of prolactinomas, the overall rates of apoplexy range between 0% 
and 2.7% (1-3). Whether post-menopausal women with prolactinoma are predisposed to pituitary 
apoplexy, or whether our finding is a mere coincidence remains to be elucidated. 
It has been previously suggested that PRL levels usually reflect tumour size (16). We attempted to 
clarify if PRL values also correlate with age at diagnosis in the group of postmenopausal women but 
our analysis did not support this.   
We found that 94% of the prolactinomas were macroadenomas with often invasive behaviour; 
supra/parasellar extension was detected in 88% of the tumours. This is in contrast to the imaging 
features seen in premenopausal females, where the majority are microadenomas: 70% in a series of 51 
females aged at diagnosis 28±1 years (16) and 85% in a series of 325 females with median age at 
diagnosis of 31 years (interquartile range 25-37) (13). However, the true prevalence of 
microprolactinomas in postmenopausal women is difficult to ascertain, as the manifestations of 
hyperprolactinemia are usually not clinically relevant and possibly a number of postmenopausal 
females harboring this type of tumour escape diagnosis. In fact, in a meta-analysis, the prevalence of 
pituitary adenoma from autopsy studies was 14.4% and, when immunohistochemical staining took 
place, PRL positive cells were identified in 25-41% of the specimens, indicating that a significant 
number of prolactinomas may not be diagnosed during the life-span (17). Published literature suggests 
that in males, prolactinomas are diagnosed at an older age, and, as in the postmenopausal women, 
there is a predominance of large and often invasive tumours (63-89% being macroadenomas) 
(2,3,16,18,19). Although not widely accepted (20), this may be attributed to a true gender difference 
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in adenoma behaviour with higher proliferative activity in males (16). It should be noted, however, 
that bias related with the selection and study of surgically-only managed tumours may influence the 
validity of these reports. 
In our series, we did not confirm aggressive adenoma behaviour in postmenopausal women; treatment 
with dopamine agonists led to normal PRL and to tumour shrinkage in 94% and 100% of the 
macroprolactinomas, respectively. Previous studies including both males and females of all ages with 
macroprolactinoma showed that cabergoline led to normoprolactinemia in 61-89% and tumour 
shrinkage (using various criteria) in 55-73% of cases (4, 21-23).  Furthermore, in a report including 
females with giant prolactinoma (defined as a tumour larger than 4 cm and PRL above 1000 mcg/l), 
7/18 (39%) of the patients were resistant to weekly doses of cabergoline ranging from 3 to 7 mg (24). 
Notably, it has been suggested that gender may not have an independent influence on success rates (4, 
25), but this view has not been confirmed by others (26) who propose that male gender is 
independently associated with resistance to cabergoline.  Reports focusing on macroprolactinomas in 
men treated with cabergoline have shown PRL normalization rates between 75.6 and 90% (19,27).  
The published literature on prolactinomas detected after menopause is limited with only one report 
published of a case series from three different Endocrine outpatient clinics in three academic centers 
from Israel, USA and Brazil (12). They authors identified 14 women who were diagnosed with a 
prolactinoma after menopause; 5/14 (36%) had no specific complaints when diagnosed, 6/14 (43%) 
had reported headaches and/or visual disturbances, 2/14 (14%) had galactorrhea and one (7%) had 
diplopia. Similar to our study, 93% had macroadenomas; suprasellar extension was seen in 57% and 
visual field defects were detected in 43%. Median PRL was 827 ng/ml (17532 mU/L) (range 85-6732 
ng/ml). Cabergoline was offered to 12 patients who were followed-up for a median period of 66 
months; in agreement with our results, optimal response was seen with PRL normalization in 10 
(83%) and reduction in adenoma size (of various degrees) in 11 (92%) of cases.  
A potential limitation of our study is the lack of data on adenoma behaviour after stopping the 
dopamine agonist treatment in this age group. Collaborative studies would be required to reliably 
address this question, and also to clarify the natural history of prolactinomas diagnosed after 
Page 12 of 20Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
12 
 
menopause and not treated with dopamine agonists (due to lack of pressure effects).  The advantage of 
our study is the inclusion of a large number of cases, which were also non-selected, consecutive and 
with detailed clinical characterization, managed with a similar approach in a single center.  
In conclusion, the clinical phenotype of prolactinomas detected in the postmenopausal period differs 
from that of premenopausal women. Macroadenomas with often invasive behaviour dominate and the 
mass effect leads to most of the signs and symptoms that prompt investigations and diagnosis. The 
rate of pituitary apoplexy was high in our series, and this, although requiring further confirmation, 
needs to be kept in mind. Nonetheless, it is very reassuring to confirm that medical treatment is highly 
effective in this group of patients.  
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Table 1. Presenting clinical, biochemical and imaging manifestations of the women with prolactinoma diagnosed in the postmenopausal period 
No 
 
Age at 
diagnosis 
Clinical Manifestations PRL at diagnosis (mU/L) 
(reference range) 
Macro/ 
Micro 
(max 
dimeter 
– cm) 
Extensions of prolactinoma 
1 78 Nausea, lethargy, tiredness, unsteadiness, 
cold intolerance (manifestations of 
hypopituitarism) 
22957 
(100-500) 
Macro 
(3.2) 
Sphenoid sinus, suprasellar displacing chiasm, 
distortion of 3rd ventricle 
2 70 During investigations for increased 
sweating and suppressed FSH 
Note: hysterectomy aged 34 (no 
galactorrhea reported at any time between 
hysterectomy and diagnosis of 
prolactinoma) 
2533 
(100-500) 
Micro 
(0.5) 
Left-sided 
 
3 70 Pituitary apoplexy with left 3
rd
 cranial 
nerve palsy 
Note: history of diabetes mellitus and 
hypertension 
At time of apoplexy 
155 
At time of prolactinoma diagnosis 
12364 
(100-500) 
Macro At time of apoplexy: sphenoid sinus, left cavernous 
sinus invasion 
 
At time of prolactinoma diagnosis: left sided mass 
projecting into the sphenoid sinus 
4 60 Tiredness, galactorrhea 
Note: history of amenorrhea for which the 
patient had been put on estrogen 
replacement therapy until age of 50 
35105 
(100-500) 
Macro 
(2.8) 
Sphenoid and cavernous sinuses, minor suprasellar 
extension 
5 58 Obstruction of left nostril, nasal drip and 
nosebleeds - CT performed to check for 
nasal polyp and biopsy of lesion 
confirmed prolactinoma 
39365 
(100-500) 
Macro 
(3.4) 
Fills sphenoid sinus, destruction of right petrous apex, 
right cavernous sinus invasion 
6 58 
 
Headaches 
Note: hysterectomy aged 29 (no 
galactorrhea reported at any time between 
hysterectomy and diagnosis of 
prolactinoma) 
4400* 
(60-540) 
Macro 
(1.6) 
Left cavernous sinus  
7 60 Visual deterioration 32898 
(100-500) 
Macro 
(3.4) 
Suprasellar, cavernous and sphenoid sinuses 
8 65 Amenorrhea since age 21 - finally 
investigated at age 65 
41680 
(60-620) 
Macro 
(3.8) 
Cavernous sinuses 
Page 18 of 20Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
2 
 
9 55 Visual deterioration 
Note: menstrual irregularities since her 
40s 
238479 
(60-620) 
Macro 
(4.2) 
Fills sphenoid sinus, extends down into the base of the 
pterygoid plate, forward into 
the region of the posterior ethmoid, laterally to 
cavernous sinuses, superiorly 
into the suprasellar system displacing optic nerves 
and chiasm, supero-anteriorly up to 
the region of the cribiform plate 
 
10 52 Headaches, visual deterioration 12040 
(60-620) 
Macro 
(4.1) 
Cavernous sinuses, encasing carotids, posteriorly 
closely related to anterior aspect of basilar artery, 
extension into middle cranial fossa, posteriorly into 
adjacent part of interpeduncular system, into the 
suprasellar area involving optic chiasm and floor of 
third ventricle 
11 67 Visual deterioration >9000* 
(65-615) 
Macro 
(2.1) 
Suprasellar, cavernous and sphenoid sinuses 
12 63 Incidentally after investigations for 
increased sweating and detection of low 
gonadotropins 
Note: periods stopped at age of 43 
9046 
(60-620) 
Macro 
(1.5) 
Left cavernous sinus, mild suprasellar extension 
13 66 Visual deterioration 
Note: periods stopped in her 30s 
5166 
(60-620) 
Macro 
(4.4) 
Extensive destruction of the clivus, spreads up onto the 
planum sphenoidale, extends into both sphenoid 
sinuses and out to the left cerebellar pontine angle, 
diaphragm of the pituitary is concave but tumour 
spreads out on the right into the mesial aspect of the 
temporal lobe 
14 58 Incidentally found after investigation for 
trigeminal neuralgia 
11401 
(100-500) 
Macro 
(1.3) 
Intrasellar 
15 72 Visual deterioration 46003 
(60-620) 
Macro 
(4.5) 
Cavernous sinuses, widely splaying the 
cavernous carotid vessels, suprasellar, impinges and 
indents on the third 
ventricle superiorly, hypothalamus and mammillary 
bodies, effacement of the prepontine cistern and mild 
indentation of the anterior pons, erosion of the dorsum 
sellae and posterior clinoid, mild 
obstructive hydrocephalus 
16 62 Pituitary apoplexy with sudden onset of 
headache, nausea, bitemporal hemianopia 
4153 
(100-500) 
Macro Sphenoid sinus and suprasellar 
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17 52 Visual deterioration 
Note: periods stopped at age of 35 
18553 
(60-620) 
Macro 
(2.1) 
Sphenoid sinus and suprasellar 
*PRL checked in a different lab. 
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Table 2. Management and outcomes of women with prolactinoma diagnosed in the postmenopausal period 
No Dopamine 
agonist 
Maximum dose  
of  
dopamine agonist 
Last dose  
of  
dopamine agonist  
Normalization  
of PRL 
Treatment 
duration  
(months) 
Adenoma 
shrinkage 
>25% in max 
diameter 
1 Cabergoline 0.5 mg/week 0.5 mg/week Yes 58 Yes 
2 None - - - - - 
3 Cabergoline 0.5 mg/week 0.5 mg/week Yes 5 Yes 
4 Cabergoline 1 mg/week 1 mg/week Yes 
 
85 Yes 
5 Cabergoline 1.5 mg/week 1.5 mg/week Yes 23 Yes 
6 Quinagolide 150 mcg/day 150 mcg/day Yes 78 Yes 
7 Cabergoline 0.5 mg/week 0.5 mg/week Yes 8 Yes 
8 Cabergoline 1 mg/week 1 mg/week Yes 139 Yes 
9 Cabergoline 1.5 mg/week 0.5 mg/week Yes 185 Yes 
10 Cabergoline 1 mg/week 1 mg/week Yes 222 Yes 
11 Bromocriptine 7.5 mg/day 7.5 mg/day Yes 183 Yes 
12 Cabergoline 0.25 mg/week 0.25 mg/week Yes 68 Yes 
13 Cabergoline 2 mg/week 1 mg/week Yes 138 Yes 
14 Cabergoline 0.25 mg/week 0.25 mg/week Yes 98 Yes 
15 Cabergoline 3 mg/week 3 mg/week No* 138 Yes 
16 Bromocriptine 2.5 mg/day 2.5 mg/day Yes 15 Yes 
17 Cabergoline 1 mg/week 0.25 mg/week Yes 145 Yes 
* Latest PRL 1147 mU/L (reference range 100-500). 
 
 
 
Page 21 of 20 Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
